Maven Securities LTD Takes $3.86 Million Position in NewAmsterdam Pharma (NASDAQ:NAMS)

Maven Securities LTD purchased a new position in shares of NewAmsterdam Pharma (NASDAQ:NAMS - Free Report) in the 4th quarter, according to its most recent Form 13F filing with the SEC. The firm purchased 150,000 shares of the company's stock, valued at approximately $3,855,000. Maven Securities LTD owned about 0.16% of NewAmsterdam Pharma at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently made changes to their positions in NAMS. National Bank of Canada FI bought a new stake in NewAmsterdam Pharma during the 4th quarter worth approximately $51,000. Mirae Asset Global Investments Co. Ltd. purchased a new position in NewAmsterdam Pharma during the fourth quarter worth about $80,000. KLP Kapitalforvaltning AS purchased a new stake in NewAmsterdam Pharma during the fourth quarter worth about $154,000. Barclays PLC grew its holdings in NewAmsterdam Pharma by 1,813.4% during the third quarter. Barclays PLC now owns 7,596 shares of the company's stock valued at $126,000 after purchasing an additional 7,199 shares during the period. Finally, The Manufacturers Life Insurance Company purchased a new stake in shares of NewAmsterdam Pharma during the 4th quarter valued at approximately $221,000. Institutional investors and hedge funds own 89.89% of the company's stock.

Analyst Upgrades and Downgrades

A number of equities research analysts have weighed in on the company. Royal Bank of Canada restated an "outperform" rating and set a $40.00 price target on shares of NewAmsterdam Pharma in a research report on Friday, January 24th. Scotiabank lifted their price objective on NewAmsterdam Pharma from $47.00 to $52.00 and gave the company a "sector outperform" rating in a research report on Thursday, February 27th. UBS Group set a $41.00 price objective on shares of NewAmsterdam Pharma in a research note on Monday, March 3rd. Needham & Company LLC cut their target price on shares of NewAmsterdam Pharma from $42.00 to $40.00 and set a "buy" rating for the company in a research report on Thursday, May 8th. Finally, HC Wainwright reiterated a "buy" rating and set a $48.00 price target on shares of NewAmsterdam Pharma in a research note on Tuesday, January 14th. Six equities research analysts have rated the stock with a buy rating, According to MarketBeat, the stock presently has a consensus rating of "Buy" and an average target price of $43.00.

NewAmsterdam Pharma Stock Performance

Shares of NAMS stock opened at $19.22 on Tuesday. NewAmsterdam Pharma has a fifty-two week low of $14.06 and a fifty-two week high of $27.29. The firm has a market capitalization of $2.11 billion, a PE ratio of -10.22 and a beta of 0.01. The stock's 50-day simple moving average is $19.45 and its 200-day simple moving average is $21.26.

NewAmsterdam Pharma (NASDAQ:NAMS - Get Free Report) last announced its earnings results on Thursday, May 8th. The company reported ($0.49) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.45) by ($0.04). The firm had revenue of $2.98 million for the quarter, compared to analyst estimates of $1.46 million. Sell-side analysts forecast that NewAmsterdam Pharma will post -1.75 earnings per share for the current year.

Insider Activity

In related news, Director James N. Topper acquired 1,135 shares of NewAmsterdam Pharma stock in a transaction on Wednesday, March 26th. The stock was purchased at an average cost of $22.49 per share, with a total value of $25,526.15. Following the purchase, the director now directly owns 3,013,569 shares in the company, valued at approximately $67,775,166.81. The trade was a 0.04% increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CAO Louise Frederika Kooij sold 150,000 shares of NewAmsterdam Pharma stock in a transaction that occurred on Tuesday, March 4th. The shares were sold at an average price of $20.37, for a total value of $3,055,500.00. Following the completion of the sale, the chief accounting officer now owns 15,000 shares in the company, valued at approximately $305,550. This trade represents a 90.91% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders own 19.50% of the company's stock.

NewAmsterdam Pharma Profile

NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases.

Want to see what other hedge funds are holding NAMS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for NewAmsterdam Pharma (NASDAQ:NAMS - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.